CAS 306296-47-9

Vicriviroc

Description:

Vicriviroc is a small molecule that functions as a CCR5 antagonist, primarily developed for the treatment of HIV infection. It selectively binds to the CCR5 co-receptor on the surface of immune cells, inhibiting the entry of HIV into these cells and thereby preventing viral replication. The compound is characterized by its ability to block the interaction between HIV and the CCR5 receptor, which is crucial for the virus's ability to infect host cells. Vicriviroc has been studied in clinical trials for its efficacy and safety profile, demonstrating potential benefits in patients with CCR5-tropic HIV strains. Its chemical structure includes a complex arrangement of carbon, hydrogen, nitrogen, and oxygen atoms, contributing to its pharmacological properties. As with many antiretroviral agents, monitoring for potential side effects and resistance development is essential during treatment. Overall, Vicriviroc represents a significant advancement in the therapeutic options available for managing HIV infection, particularly in cases where traditional therapies may not be effective.

Formula: C₂₈H₃₈F₃N₅O₂

InChI: InChI=1S/C28H38F3N5O2/c1-19-16-35(14-15-36(19)24(17-38-5)22-6-8-23(9-7-22)28(29,30)31)27(4)10-12-34(13-11-27)26(37)25-20(2)32-18-33-21(25)3/h6-9,18-19,24H,10-17H2,1-5H3/t19-,24-/m0/s1

InChI key: InChIKey=CNPVJJQCETWNEU-CYFREDJKSA-N

SMILES: [C@@H](COC)(N1[C@@H](C)CN(CC1)C2(C)CCN(C(=O)C=3C(C)=NC=NC3C)CC2)C4=CC=C(C(F)(F)F)C=C4

Synonyms:

• (4,6-Dimethyl-5-pyrimidinyl)[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methyl-1-piperidinyl]methanone
• 5-({4-[(3S)-4-{(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl}-3-methylpiperazin-1-yl]-4-methylpiperidin-1-yl}carbonyl)-4,6-dimethylpyrimidine
• 5-[4-[4-[2-methoxy-1(R)-[4-(trifluoromethyl)phenyl]ethyl]-3(S)-methylpiperazin-1-yl]-4-methylpiperidin-1-ylcarbonyl]-4,6-dimethylpyrimidine
• Methanone, (4,6-dimethyl-5-pyrimidinyl)[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methyl-1-piperidinyl]-
• Mk 7690
• Piperidine, 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methyl-
• Sch-417690
• Sch-D
• Vicriviroc
• Vicroviroc

Methanone, (4,6-dimethyl-5-pyrimidinyl)[4-[(3S)-4-[(1R)-2-methoxy-1-[4-(trifluoromethyl)phenyl]ethyl]-3-methyl-1-piperazinyl]-4-methyl-1-piperidinyl]-

CAS: 306296-47-9

Formula: C₂₈H₃₈F₃N₅O₂

Molecular weight: 533.6288

Ref: IN-DA0030PD

Vicriviroc

CAS: 306296-47-9

Vicriviroc, also known as MK4176 is a CCR5 antagonist.

Formula: C₂₈H₃₈F₃N₅O₂

Color and Shape: Solid

Molecular weight: 533.63

Ref: TM-T69478

Vicriviroc

CAS: 306296-47-9

Formula: C₂₈H₃₈F₃N₅O₂

Molecular weight: 533.64

Ref: 4Z-V-031001

Vicriviroc

CAS: 306296-47-9

Vicriviroc is an investigational pharmaceutical compound, specifically classified as an HIV entry inhibitor. It originates from a synthetic source, designed to target the CCR5 co-receptor on human immune cells. The mode of action involves blocking this co-receptor, thereby preventing the HIV virus from binding and fusing with the host cell membrane. This inhibition effectively obstructs the virus's ability to enter and infect the host cells, particularly those within the chemokine receptor family.

Formula: C₂₈H₃₈F₃N₅O₂

Purity: Min. 95%

Molecular weight: 533.63 g/mol

Ref: 3D-FV104151